{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_000177491.4:c.1256A>G",
          "cDNA Change": {
            "transcript": "NM_000177491.4",
            "ref": "A",
            "alt": "G",
            "position": "1256"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "G",
            "position": "419"
          },
          "Description in input context": "This variant is present in a patient exhibiting early-onset Parkinsonism."
        },
        {
          "HGVS": "NM_000177491.4:c.1557T>C",
          "cDNA Change": {
            "transcript": "NM_000177491.4",
            "ref": "T",
            "alt": "C",
            "position": "1557"
          },
          "Protein Change": {
            "ref": "T",
            "alt": "C",
            "position": "519"
          },
          "Description in input context": "The substitution alters a highly conserved amino acid, potentially disrupting kinase activity."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Early-Onset Parkinsonism",
    "MONDO": "MONDO:0008947"
  },
  "Experiment Method": [
    {
      "Assay Method": "In vitro Kinase Assay",
      "Material used": {
        "Material Source": "Recombinant Protein",
        "Material Name": "GST-LRRK2 (R1286Q)",
        "Description": "Recombinant GST-tagged LRRK2 protein containing the R1286Q pathogenic variant was utilized for kinase activity assessments."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000177491.4:c.1256A>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Decreased Kinase Activity",
          "Result Description": "The c.1256A>G variant resulted in approximately 40% reduction in kinase activity compared to wild-type LRRK2. This suggests a loss-of-function mechanism."
        },
        {
          "Variant": "NM_000177491.4:c.1557T>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased Susceptibility to Phosphorylation",
          "Result Description": "The c.1557T>C variant exhibited increased susceptibility to phosphorylation at Serine 1292, potentially leading to altered protein interactions."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Each condition was assessed in triplicate biological replicates to ensure reproducibility."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each biological replicate was subjected to three technical replicates within the assay."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 served as the positive control, demonstrating normal kinase activity."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "A kinase-deficient mutant LRRK2 was employed as a negative control, exhibiting negligible kinase activity."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA followed by post-hoc t-tests were used to analyze the data and determine statistical significance."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Kinase activity within the range of 80-120% of the control group is considered normal.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Kinase activity below 80% or above 120% of the control group is indicative of an abnormal response.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}